Literature DB >> 27038363

Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.

T Vergou1, A E Moustou1, C Antoniou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27038363     DOI： 10.1111/jdv.13658

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept.

Authors:  Chong Won Choi; Ji Su Lee; Da-Ae Yu; Bo Ri Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2019-01-02       Impact factor: 1.444

2.  Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea.

Authors:  Chong Won Choi; Seungkeol Yang; Gwanghyun Jo; Bo Ri Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2018-10-26       Impact factor: 1.444

3.  Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis.

Authors:  Chong Won Choi; Ji Young Choi; Bo Ri Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

4.  A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.

Authors:  Emmanouil Charakopoulos; Ioannis Spyrou; Nora-Athina Viniou; Nefeli Giannakopoulou; Sevastianos Hatzidavid; Panagiotis Theodorou Diamantopoulos
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.